The DNAJA1 Knockout 786-O Polyclonal Cells constitute a heterogenous population of 786-O human clear cell renal carcinoma cells engineered by CRISPR/Cas9-mediated gene disruption to eliminate DNAJA1 expression. This polyclonal knockout model avoids clonal selection, offering a genetically diverse loss-of-function system for functional studies.
The parental 786-O cell line originates from a primary clear cell adenocarcinoma of the kidney and carries a mutation in the von Hippel-Lindau (VHL) tumor suppressor, resulting in constitutive activation of hypoxia-inducible factor pathways. This well-characterized VHL-null background is widely employed to investigate hypoxia signaling, angiogenesis, and metabolic dysregulation in renal cell carcinoma.
DNAJA1 encodes an Hsp40 co-chaperone that recruits client proteins to HSP70, stimulating its ATPase activity to drive protein folding, trafficking, and degradation. DNAJA1 directly interacts with HSP70 and HSP90 within the chaperone machinery, and also binds to IKK?? and BAX, thereby integrating chaperone function with NF-??B signaling and apoptotic regulation. Under proteotoxic stress, HSF1 upregulates DNAJA1, increasing the cellular capacity to manage misfolded proteins. This positions DNAJA1 as a key mediator of the heat shock response and a modulator of the balance between cell survival and programmed death.
In 786-O renal carcinoma cells, the VHL deficiency creates a state of heightened proteotoxic and oxidative stress, which can be exploited by the tumor through heightened chaperone activity. DNAJA1 may support adaptation to this stress, promoting NF-??B-driven survival and inhibiting BAX-mediated apoptosis. Disrupting DNAJA1 in this polyclonal pool permits assessment of heterogeneous response to chaperone impairment, elucidating how loss of this co-chaperone affects tumor cell viability, stress resilience, and signal transduction in a model relevant to clear cell renal carcinoma.
Applications include examining the impact of DNAJA1 loss on HSP70 client processing by co-immunoprecipitation and immunoblotting, quantifying apoptosis induction via Annexin V assays, and monitoring NF-??B transcriptional activity through luciferase reporters. The model is suitable for RNA-seq-based transcriptomic profiling and cell proliferation studies to identify synthetic lethal partners. These polyclonal cells serve as a versatile platform for cancer biology, proteostasis research, and drug discovery. For further technical information or assistance with experimental design, please contact Ascent Research.
